Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04351620 · ClinicalTrials.gov registry record · Phase 1
High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04351620 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 12 participants.
The verdict
NCT04351620, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.
Interventions
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2020-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04351620
The ClinicalTrials.gov registry entry for NCT04351620 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine is the first listed.
NCT04351620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04351620 about?
NCT04351620 is a clinical study titled "High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19". This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.
What is the current status of trial NCT04351620?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-04-20. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT04351620?
The interventions under investigation include: Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04351620?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.